Pfizer Trading forecasts and signals

Moderna, Moderna's biotech company, has sued Pfizer and its German partner BioNTech for patent infringement in developing the first COVID-19 vaccine approved in the US, claiming they copied technology developed by Moderna years before the pandemic.A claim for monetary damages in an unspecified amount was filed in the U.S. District Court in Massachusetts. The lawsuit will also be filed in the Dusseldorf District Court in Germany, according to a press release from Moderna."We are filing these lawsuits to protect the innovative mRNA technology platform that we developed, invested billions of dollars in creating and patented during the decade preceding the COVID-19 pandemic," Stefan Bansel, CEO of Moderna, is quoted as saying.The BioNTech/Pfizer/BioNTech vaccine was approved for emergency use by the US Food and Drug Administration (FDA) in December 2020, and a week later by Moderna.The Moderna coronavirus vaccine, its only commercial product, generated revenue of $10.4 billion this year, while the Pfizer vaccine generated about $22 billion.Pfizer said the company is confident in its intellectual property and will vigorously defend itself against the allegations.Moderna said its lawsuit is not aimed at preventing people from getting vaccines, and repeated its promise never to apply its COVID-19 vaccine patents in 92 low- and middle-income countries.But the issuer said it expects companies such as Pfizer and BioNTech to respect its intellectual property rights and is demanding royalties from sales after March 8, 2022, excluding sales to the U.S. government or low-income countries.Pfizer shares fell 2.25% on the NYSE in trading on August 26, and Moderna shares on the NASDAQ lost 3.77%. U.S. BioNTech shares on the NASDAQ fell by ...

The American pharmaceutical company Pfizer Inc and the German BioNTech have signed a deal with the US government worth $3.2 billion for the supply of 105 million doses of their joint COVID-19 vaccine, which can be delivered as early as the end of this summer. The updated vaccine is specially adapted to the "omicron" strain and caused a higher immune response.The mass use of booster doses of the updated vaccine from Pfizer and BioNTech in order to prevent infections with the Covid-19 coronavirus, including the omicron strain, has been approved by the US Food and Drug Administration. The agency also allowed children aged 12 to 15 to be vaccinated with it.Most of the new cases of Covid-19 coronavirus infection in the United States in 2022 were due to infections with the omicron strain, which is spreading quite quickly, so the delivery of 105 million doses of the vaccine this summer will help contain the spread of coronavirus infection at the peak of the disease, which most often falls during the cold season. Today, Pfizer's stock prices are rising by 0.4% on the premarket, a slight increase is due to the fact that this transaction was most likely ...

The American pharmaceutical company Pfizer and the German BioNTech reported that a booster dose of updated versions of their COVID-19 vaccine caused a higher immune response against the omicron strain.The vast majority of new cases of infection with the Covid-19 coronavirus in the United States in 2022 are due to infections with the omicron strain. Therefore, an updated vaccine that can be effective against the omicron strain was necessary. The American Food and Drug Administration approved at the end of 2021 the mass use of booster doses of the updated vaccine from Pfizer and its partner BioNTech in order to prevent infections with Covid-19 and its newer strains, including omicron, and also allowed it to vaccinate children aged 12 to 15 years."The news is definitely good, but last Friday, Pfizer's stock quotes on the New York Stock Exchange closed with a 3% increase, and today the shares are slightly declining on the premarket, since the event has already been taken into account in prices," analysts ...

The biotech company Enanta Pharmaceuticals, Inc. has filed a lawsuit against the pharmaceutical company Pfizer, Inc., accusing it of patent infringement in the production of the antiviral drug Paxlovid.In early June, Enanta received a patent from the regulator based on an application dated July 2020, which describes the coronavirus protease inhibitors invented by the company's scientists. Enanta believes that Pfizer used these developments to produce its Paxlovid drug. However, Enanta understands its importance to patients without seeking an injunction. The Company expects fair compensation.Paxlovid is still in development, but Pfizer already predicts a profit from its sales in 2022 in the region of $22 billion. At the same time, Enanta does not plan to demand a ban on its production or sale, apparently we are talking about receiving at least some financial deductions from the sale of the drug. In our opinion, if Enanta wins this lawsuit, its shares may significantly rise in price, if not, it will damage its reputation and its shares will continue to decline.Pfizer shares on the NYSE on June 21 rose 3.4% to $48.11 per ...

The American pharmaceutical company Pfizer will acquire 8.1% of the shares of the French vaccine company Valneva. Pfizer will buy shares at 9.49 euros per paper, spending 90.5 million euros ($95.24 million).Valneva will direct the funds received from Pfizer to support the development of a drug against Lyme disease, which is in the third stage of research. Companies have been cooperating since 2020 to combat this disease.Pfizer shares fell 2% on June 17, to $46.53 per paper. Valneva's stock quotes rose sharply to 9.09 euros per paper on the background of the news. According to analysts, Pfizer overpaid a rather large premium by purchasing Valneva shares, whose quotes before the news announcement were only 7.94 euros per ...

Some doctors in the United States are re-considering the need to take Pfizer's Paxlovid tablets against COVID-19 in patients with a lower risk of developing a severe form of the disease, as well as vaccinated. In such cases, doctors try not to prescribe the drug. At the same time, the recommendation still remains for people who have serious illnesses or are over 75 years old.For the company itself, doubts about the effectiveness of its drug are not the best news: after all, it earned revenue of $26 billion in the 1st quarter of 2022 from the sale of Paxlovid and coronavirus vaccines, which exceeded the revenue value by 77% in the same quarter of 2021. Pfizer shares on the New York Stock Exchange on Friday fell by 0.15% to $53.91, on the OTC market today they are trading in a weak ...

Over the past two weeks, the S&P 500 index has adjusted by 6.17%, updating the lows of March last year. NASDAQ Composite tested the values of November 2020. The real yield of 10-year treasuries has moved into positive territory, which reduces investors' interest in high-risk assets.The Fed's "hawkish" policy continues: at the May meeting, the key rate was expected to be raised by 50 bps, to 0.75–1%. Plans for further increases remain, but an extension of the target range by 75 bp is not yet being considered. The regulator plans to start reducing the balance sheet as early as June 1, gradually increasing the volume to $95 billion per month. By the end of 2022, the Fed's portfolio will decrease from the current $8.9 trillion by about 6%.The reporting season is coming to an end: the revenue and profit of the reported issuers (91% of companies) increased by 13.4% and 9.1%, respectively. Occidental Petroleum, Pfizer, AMD, and Moderna showed the best results. Did not meet the expectations of analysts of Electronic Arts, The Walt Disney, Coinbase.Ideas and recommendationsBank of America Corporation retains a leading position in the lending market and is seen as the main beneficiary of the interest rate increase. A diversified business model and active development of digital banking will contribute to achieving the $46 target on the horizon of the year.Coinbase Global, the largest crypto exchange, announced a significant drop in revenue in the 1st quarter of 2022. Among the reasons: the weakening of investor activity, a reduction in trading volume due to the correction of cryptocurrencies. Management expects a decrease in commission income and income from paid services while maintaining operating expenses at the same level. Pfizer acquires biopharm company Biohaven Pharmaceutical for $11.6 billion. Pfizer seeks to compensate for the potential decline in revenue from COVID-19 treatment drugs and directs profits from their sale to acquire biotech companies that have promising developments. Pfizer forecasts revenue from this direction in the current year at the level of $54 billion.ExpectationsThe S&P 500 tested support in the area of 3860-3900 points and showed a rebound from local lows. A short-term recovery of quotations is possible. However, with the gradual tightening of financial conditions, the medium-term trend remains downward. The next resistance level for the benchmark is at 4,200 points, and the nearest support is at 3,800 ...

The market the day beforeThe main American stock indexes ended the trading session on May 10 in different directions. The S&P 500 rose 0.25% to 4001 points, the Nasdaq added 1.30%, the Dow Jones lost 0.26%. Technology companies (+1.52%) and energy companies (+0.91%) showed positive dynamics. Representatives of the real estate sector (-2.22%) and utility providers (-1.21%) looked worse than the market.Company newsBiohaven Pharmaceutical (BHVN: +68.39%) has received a purchase offer from Pfizer Corporation (PFE: +1.75%). If implemented, the deal, estimated at $11.6 billion, will be the largest for Pfizer since 2016.Sony Group (SONY: +1.43%) reported a twofold increase in operating profit for the first quarter due to large PlayStation sales volumes. The company plans to launch an annual share repurchase program worth $1.54 billion starting in May.Upstart (UPST: -56.42%) exceeded consensus expectations regarding financial indicators for the first quarter, but lowered its own revenue forecast for the current year, taking into account the negative impact of interest rate increases and macroeconomic uncertainty.We expectToday, the publication of data on the dynamics of consumer inflation for April is in the focus of investors' attention. Futures on US indices indicate the likelihood of an upward movement during the upcoming trading, as investors expect a slowdown in price growth from March +1.2% mom to 0.2%, and in annual comparison, inflation, according to market-wide forecasts, will be 8.1% after 8.5% in March. This process should be facilitated by the Fed's actions aimed at curbing price growth. If the expected trend is confirmed, the Fed will be able to continue the gradual transition to a neutral level of the key rate of 2% without additional aggressive measures to tighten the PREP.On the eve of the President of the Federal Reserve Bank of Cleveland, Loretta Mester, said that she considers it preferable to continue raising the discount rate by 50 bps in June and July, although she allowed the possibility of changing the rate above the neutral level if necessary. The head of the Federal Reserve Bank of New York, John Williams, who adheres to the same position, warned that the tightening of credit conditions will slow down the pace of hiring and may cause some increase in unemployment. Williams predicts a decline in personal expenditure Index (PCE) inflation to 4% by the end of the year, with it reaching 2.5% in 2023 and returning to the target of 2% in 2024. According to the official, this year the labor market and the US economy will remain stable, and GDP will grow by 2%.Trading on May 11 on the sites of Southeast Asia ended in positive territory. Japan's Nikkei gained 0.18%, China's CSI 300 rose 1.44%, Hong Kong's Hang Seng rose 0.97%. EuroStoxx 50 has been rising 1.62% since the opening of trading.The price of Brent crude oil futures dropped to $102.5 per barrel. Gold is trading at $1,841 per troy ounce.In our opinion, the S&P 500 will hold the upcoming session in the range of 3380-4030 points.MacrostatisticsThe US consumer price index for April will be published today. The consensus forecast assumes that core consumer inflation will be 0.4% mom and 6.0% YoY after 0.3% mom and 6.5% YoY in March.Sentiment IndexThe sentiment index rose 1 point to 36.Technical pictureThe S&P 500 closed the gap, testing the April 2021 marks. At the end of the session on May 10, the benchmark was fixed at the psychologically important level of 4000 points. The dynamics of futures on the premarket indicates a gradual recovery of quotations. Taking into account the technical oversold stocks, a short-term rebound is possible, but the RSI and MACD indicators confirm the continuation of the "bearish" trend. The closest support for the broad market index is the range of 3850-3900 points.ReportsWalt Disney (DIS) will present quarterly results today. The consensus assumes that the media giant's revenue will increase by 29% YoY and exceed $20 billion, and adjusted EPS will rise by 51% to $1.19. The expected high growth rates are largely due to the weak results over the past year, which have experienced the pressure of another period of severe anti-covid restrictions. The factors of support for the Disney indicators are the restoration of the segments of film distribution, TV advertising, as well as the resumption of the full functioning of amusement parks and hotels. Last quarter, Disney's results were higher than market expectations. Revenue increased by 34% YoY, exceeding the consensus forecast by 4.8%. The main driver of growth then was the amusement park segment. We believe that this direction will continue to demonstrate faster recovery rates than expected, thanks to increased traffic and an increase in average revenue per visitor. Earlier, Comcast had already announced the exceptionally high demand observed in Universal amusement parks. The weak point in Disney's reporting may be the results of the streaming direction. However, the company is able to outpace Netflix thanks to the upcoming summer expansion in 42 countries of Eastern Europe, Africa and the Middle East. This driver will provide an accelerated expansion of the base of subscribers of the Disney+ service, whose number by the end of September, according to our estimates, is capable of growing to 150-155 million. As of the end of 2021, Disney's streaming audience was almost 130 ...

The JPMorgan Chase & Co (JPM) annual healthcare conference ended in San Francisco on January 13. This event with a forty-year history is considered one of the most significant in the medical community: pharmaceutical company executives participate in it, important statements about mergers and acquisitions are made on its site, new drugs are presented and breakthrough research is announced.Taking into account the new realities, for the second year in a row, the event is held in an online format. Let's list the most interesting industry trends that were outlined in the speakers' speeches.The use of RNA is recognized as the main trend in pharmacologyRibonucleic acid (RNA) is one of the three main macromolecules in the cells of all living organisms. Although the functions of RNA are not yet fully understood, studies show that this acid plays an important role in the coding and regulation of genes.Ribonucleic acid has attracted increased attention in connection with the development of vaccines against Covid-19. The previous generation of vaccines involved the introduction of a weakened virus into the body to form a subsequent immune response. Moderna (MRNA) and Pfizer (PFE) vaccines, created on the basis of informational RNA, work differently: they ”teach" human cells to produce a protein that triggers an immune response to prevent infection with coronavirus. Thus, the immune system of a vaccinated person is trained to recognize a protein containing Covid-19 and produce antibodies to it.As part of the conference, Pfizer announced the conclusion of three agreements with smaller industry players to accelerate RNA developments. The company sees a huge potential for RNA-based drugs - in particular, in the treatment of cancer and rare diseases. Amgen's interest in collaborating with Arrakis Therapeutics in the study of RNA is widely discussed, which could result in an order for several billion dollars for the latter. Pharmaceutical giants Johnson & Johnson (JNJ) and Eli Lilly (LLY) have so far limited themselves to restrained statements that they are exploring the possibilities of RNA technologies.Coronavirus pushes for partnerships instead of mergersFor the second year in a row, the healthcare sector has not heard about major deals. The coronavirus has shuffled all the cards. Previously, when a breakthrough technology was discovered, a pioneer was usually expected to be absorbed at a premium to the market, but the pandemic has taught companies to think in a new way, and now they are increasingly inclined to partnerships.The most telling example was the collaboration in the development of a coronavirus vaccine between Pfizer and BioNTech (BNTX). Through partnership, large players actually place an order for development to specialized companies with lower turnover. As a result, both sides benefit: pharmaceutical giants save money, and their partners receive orders and financing.Covid-19 ComebackHaving not had time to fully vaccinate against Covid-19, humanity faced a threat in the form of a new and more contagious variant of the coronavirus - "omicron". A strain from South Africa sets anti-records for morbidity in developed countries, involving pharmaceutical giants in a new development race.Some companies at the conference reported on the supply of their drugs against coronavirus. So, Moderna reported that its sales in 2021 amounted to $ 18.5 billion. GlaxoSmithKline (GSK), in partnership with Vir Biotechnology (VIR), reported on the supply to the US government of 600 thousand doses of the drug for the treatment of Covid-19 sotrivimab. Novavax (NVAX) announced that it has already made the first shipments to Europe of its Covid-19 vaccine, but did not specify the volume of orders. And Gilead Sciences (GILD) has informed that its drug remdesivir may soon be approved by the US regulator for the treatment of coronavirus.As for the development of drugs aimed directly against the omicron strain, only Regeneron (REGN) and Pfizer have made statements about this. Regeneron is going to test the treatment of omicron with antibodies in the first quarter, and Pfizer spoke about the progress in creating a new vaccine against Covid-19, which will also work against the new strain.There is an opinion that omicron as an opportunity rather than a threat. Perhaps omicron is our salvation from coronavirus restrictions, since the body of vaccinated people, having met with a new strain of virus from South Africa, gives an immune response, which can be considered as an alternative to booster vaccination. Which, in a global effect, can give massive protection against coronavirus infection.Patent diversificationLarge pharmaceutical companies are in a hurry to reassure investors who are beginning to pay attention to the patent terms of drugs that occupy a large share in their sales.As a rule, after the expiration of a patent for a particular drug, the market is flooded with its cheaper copies, which significantly reduces the revenue of the manufacturer of the original drug. Therefore, investors expect a diversified portfolio of developments from pharmaceutical giants, which will include not only expensive cancer drugs, but also a wide range of medicines for other diseases.For example, the patent of the anti-cancer drug from Merck & Co (MRK) Keytruda expires in 2028. Total sales of this drug for 2020 amounted to $14.4 billion, which accounted for 30% of Merck's revenue. If the company does not explain to investors before the expiration of the exclusivity period how it is going to compensate for the upcoming "loss” of sales volumes, the market reaction can be very negative.Analysts' opinionAn endless "arms race" continues in the pharmaceutical sector. Since breakthrough technologies and patents provide only a temporary competitive advantage, companies have to constantly set themselves new and new goals.However, the JPMorgan conference reflected some changes in the behavior of both pharmaceutical companies and their investors. Industry representatives confirmed their propensity to create partnerships, and investors confirmed their demands for diversification of development portfolios.The most obvious new trend among the elite of pharmacology has been the use of ribonucleic acid to encode the human immune system. It is assumed that with the proper development of technology, scientists will be able not only to achieve the necessary immune response to various infectious diseases, but also to eliminate defects in hormones or blood quality.And the main intrigue remains who will be the first to develop a vaccine against the omicron strain. Leading pharmaceutical giants are studying its characteristics, causes of origin and the reaction of previously vaccinated people to it. Thus, the beginning of this year is similar to the beginning of the previous one. Back then, we were also on the verge of creating a working version of the vaccine and watched the deadly virus walk around the planet ...

A couple of steps away from the new year, many are trying to predict the direction of market winds over the next year, and maybe several. We have also analyzed promising ideas of stock exchanges, and today we will share them with you. In general, everything promising in the coming year is connected with the healthcare sector. Next, let's talk about the two most promising companies in this segment.NovavaxNovavax company was one of the first to enter the championship in the development and creation of a vaccine, but in this case it is still far from the podium. Does the company have real prospects? Let's talk about this further.At the beginning of the year, many experts argued that it was simply not advisable to get involved in the company's struggle. This was due to the fact that there were already many manufacturers of similar drugs, and there was not enough space for new ones. As a result, the experts' "verdict" turned out to be reckless, and today many are confident that the company's assets are among the most attractive in the coming year.The vaccine was one of the first to be released in Europe. It is based on a protein, which in the future can become an alternative for patients who refuse to be vaccinated by Pfizer and Moderna, developed on the basis of RNA.In the spring of 2021, she presented the results of testing a new vaccine to the world, and in mid-summer, repeated tests were conducted in America. The effectiveness of the drug according to the test results ranges from 89.7% to 90.4%. This high indicator allowed the drug to get into the top three most effective, and the company to become a leader in the world market of manufacturers.Immediately after the publication of the results, it was expected that the company's assets should increase in value, but problems with bureaucratic hitches and permission to use the vaccine on world markets led to the fact that the share price remained in place, and subsequently even declined.Different sources explain this fall in different ways. Some argue that there are no special technological lines for the production of the drug in the United States. Others are sure that the drug simply does not meet the standards established in the state, contains unnecessary impurities that can cause a lot of side effects.Today, the drug is recognized in several countries of the world, including Indonesia, India. The vaccine has the permission of the WHO and the euroregulator, together with the submission of the application, it has received permission in several other countries.Today Novavax is awaiting regulatory approval in many countries around the world, including Australia, Canada, South Korea, and the United Kingdom. To accelerate the production of the drug, the company is sponsored by a number of large-scale organizations, including the Gates Foundation and even the American government.If new strains of coronavirus continue to appear, the disease will be transferred to the category of endemic. That is why vaccination will very soon become a routine procedure, and it is also likely that the demand for combined drugs will grow, which the company is currently testing.It is not enough to be able to treat well, you also need to correctly diagnose diseases. That is why next we will talk about the manufacturer of medical equipment for diagnostics.Thermo Fisher ScientificThermo Fisher Scientific is geographically located in Massachusetts. It is one of the leaders in the production of diagnostic tools and equipment used in laboratory and outpatient settings, as well as consumables. The production of coronavirus vaccines and medicines for this pathology is considered to be an equally significant area of activity of the enterprise. From the beginning of the pandemic to the present time, the demand for the company's products remains at a height, so the company today occupies a leading position in the field of medicine.In the spring of 2021, the International Health Association granted the company a license to produce SARS-CoV-2, a test for detecting covid-19. The volume of revenue received only from anti-weed products today has already amounted to $2.05 billion. With the emergence of new strains of coronavirus, the demand for the company's products will only grow.The TMO quarterly report, released on October 27, turned out to be quite strong. Revenue exceeded last year's figure by 15%, as well as by $ 1.2 billion in monetary terms. In total, it amounted to 37.1 billion dollars. According to forecasts, the amount of revenue will increase by $1 billion, and will amount to $7.7 billion.The forecast for this indicator was $40.5 billion, which shows the excellent position of the enterprise, especially for modern market realities. The growth of the company's asset price index exceeded the S&P 500, and reached 40%. With great probability, we can say that the group's positions will continue to be stable.Another trend of the century is electric carsThe vast majority of major analysts last year warned against acquiring Nio assets. At that moment, no one could have thought that the company's market capitalization could reach $90 billion. The volume of cars produced at the same time is 20 thousand units annually.However, over the past year, the company has managed to become an industry leader, and excellent financial results are expected in 2022. This is despite supply disruptions and other problems associated with the pandemic. The company has several new products that will help it increase its market share in China, and take a strong position on it.In the autumn of 2021, the number of cars produced by the company reached 10,900 units, which indicates an active growth in demand for cars with an engine capacity of more than 130,000 per year. The company is going to release about 600 thousand units of cars by the end of 2022. Nio's management plans to introduce three new electric cars to the world market. If the sales growth of cars remains at the planned indicators, then Nio may well have the opportunity to bypass Tesla by this parameter. At least in the Chinese market.An important advantage of the enterprise is the already launched Battery-as-a-service or BaaS program. It allows you to make a monthly payment, which allows you to change the battery on an electric car in the future or update the battery charge. It will also be possible to buy a car without a battery, rearranging it from old equipment.This system will allow the company to receive high-margin revenue in the long term. In addition, we should expect an increase in customer loyalty to the products. The company's assets showed a 13% growth in 2020, but during 2021 they managed to fall by 44%. Today they are stable at around $30. We are waiting for strong growth.Basic Attention TokenIt is already impossible to imagine the financial world without cryptocurrency. How to choose correctly between all the options – Bitcoin, Litecoin, Ethereum and others, and not be left out? An interesting option is offered by the Basic Attention Token.Over the past six months, investors' attention has been focused on tokens supporting the application. If we take into account that since the beginning of the year, the growth of bitcoin has approached 73%, then this is a minuscule compared to the start of the Siba-anu meme token, which soared to 47000000%. However, the main investment flow today is considered to be directed to a cryptocurrency that provides support for applications.In the large list of tokens, the Basic Attention Token from Brave Software deserves special attention. In particular, the token is especially attractive for investing for a long period. The company is now managed by B. Eich is the founder of Mozilla and JavaScript.Coins are mined using the Brave browser, where they are obtained by viewing advertising content. The web browser provides a high degree of security due to the built-in ad blocker and functions to block the collection of user data. Allows you to personally view ads released by program partners, as well as earn tokens by viewing it.Throughout December, bears dominated the cryptocurrency market, which negatively affected the VAT. As a result, the price of the token fell by 30% from the historical highs seen at the end of autumn. However, Bravo is confident that the price will recover its indicators very ...